Cargando…
Global Health Resource Utilization and Cost-Effectiveness of Therapeutics and Diagnostics in Immune Thrombotic Thrombocytopenic Purpura (TTP)
In this review, we examine the current landscape of health resource utilization and cost-effectiveness data in the care of patient populations with immune thrombotic thrombocytopenic purpura. We focus on the therapeutic (therapeutic plasma exchange, glucocorticoids, rituximab, caplacizumab) and diag...
Autores principales: | Butt, Ayesha, Allen, Cecily, Purcell, Adriana, Ito, Satoko, Goshua, George |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10420213/ https://www.ncbi.nlm.nih.gov/pubmed/37568288 http://dx.doi.org/10.3390/jcm12154887 |
Ejemplares similares
-
Ipilimumab-induced thrombotic thrombocytopenic purpura (TTP)
por: King, Jeanelle, et al.
Publicado: (2017) -
Unresponsive Thrombotic Thrombocytopenic Purpura (TTP): Challenges and Solutions
por: Lemiale, Virginie, et al.
Publicado: (2021) -
Tacrolimus associated thrombotic thrombocytopenic purpura (TTP) and stroke in the young
por: Maramattom, Boby Varkey, et al.
Publicado: (2015) -
Thrombotic thrombocytopenic purpura (TTP)-like syndrome in the HIV era
por: Louw, Susan, et al.
Publicado: (2018) -
Autoimmune thrombotic thrombocytopenic purpura (TTP) associated with COVID-19
por: Albiol, Nil, et al.
Publicado: (2020)